The argument can be put the other way. If you are very confident about the results of a phase 3 trial, and you have the money to do a phase 3 trial, why license it before that is complete?
Is it possible that there have been offers already, which have been rejected?
The later the stage at which a drug is licensed, the lower the risk to the licensee and therefore the higher the license fee/royalties that can be negotiated. Each stage of Apricitabine's development is getting better and better results, so why stop now?
- Forums
- ASX - By Stock
- AVX
- dont underestimate importance of phase 2
dont underestimate importance of phase 2, page-11
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)